Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis ; volume:120 ; number:05 ; year:2020 ; pages:728-736
Thrombosis and haemostasis ; 120, Heft 05 (2020), 728-736
- Contributor
-
Chowdary, Pratima
Fischer, Kathelijn
Collins, Peter W.
Cotterill, Amy
Konkle, Barbara A.
Blanchette, Victor
Pipe, Steven W.
Berntorp, Erik
Wolfsegger, Martin
Engl, Werner
Spotts, Gerald
- DOI
-
10.1055/s-0040-1709519
- URN
-
urn:nbn:de:101:1-2020080708523959752434
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chowdary, Pratima
- Fischer, Kathelijn
- Collins, Peter W.
- Cotterill, Amy
- Konkle, Barbara A.
- Blanchette, Victor
- Pipe, Steven W.
- Berntorp, Erik
- Wolfsegger, Martin
- Engl, Werner
- Spotts, Gerald
Other Objects (12)
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia